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Abstract
Purpose: Few reports have been published on the evaluation of stem cell auto transplantation for chemosensitive sarcomas.
Some suggest benefit, others do not. We present results of 24 patients with sarcoma undergoing autotransplantation at a
Canadian institution.
Patients and Methods: Twenty-four patients were treated between 1988 and 1998: 23 were  18 years (median 27; range
12–56); genders were equal; 12 patients had Ewing’s sarcoma. At diagnosis, 12 (50%) had metastatic disease. Prior to
autotransplant, all had  1 chemotherapy regimen. Fourteen (58%) were in complete remission (CR) and seven (29%) had
minimal residual disease. All received etoposide 60mg/kg (Day  4), melphalan 140mg/m
2 on (Day  3) and a stem cell
reinfusion (Day 0).
Results: Three patients (12.5%) were alive and disease-free with median follow-up of 92 months (80–142); one was alive
with disease 32 months post-autotransplant. Twenty had died (disease, 17; transplant-related, 2; unknown, 1). Of the four
alive, three had Ewing’s sarcoma, one alveolar rhabdomyosarcoma, and all were in CR at transplant. Median time to relapse
was 6 months (2–59). Sixteen of 18 (89%) relapsed within 1 year. Median overall survival was 10 months (0–137). A trend
towards improved survival (P¼0.07) was evident for patients in CR prior to autotransplant.
Conclusions: Stem cell autotransplantation does not benefit most patients with sarcoma. A subgroup of high-risk patients in
CR may fare better and warrant further study.
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Introduction
Sarcomas are rare tumors, and their incidence shows
a bimodal distribution. They occur in children and
young adults (0–20 years), but the highest numerical
incidence is between ages 50 and 80 years. Six
thousand new soft tissue sarcomas, 250 Ewing’s
sarcomas, 750 osteosarcomas and 450 chondrosar-
comas are diagnosed yearly in the U.S.
1
The initial management of patients with sarcomas
usually includes surgery. Radiotherapy and/or
chemotherapy may also be added before or after
surgery. Although sarcomas have historically been
described as relatively chemoresistant, those seen
predominantly in the pediatric population, e.g.,
embryonal rhabdomyosarcomas, osteosarcomas and
Ewing’s sarcomas, can be responsive to chemo-
therapy. Despite best efforts, inoperable locally
advanced and metastatic sarcomas are rarely curable
with conventional therapy. For adult soft tissue
sarcomas, the median survival from recognition of
metastatic disease can be quite variable but tends to
be in the order of 8–12 months in most series
2–6.
However, a small but significant proportion will
experience longer survival and up to a quarter of
patients will be alive 2 years following a diagnosis of
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tumors, some factors tend to predict a worse
prognosis with regards to response to treatment
and survival of patients with advanced soft tissue
sarcomas (ASTS). These include a non-pediatric
histology, non-extremity primary sites, poor response
to chemotherapy, liver metastases and poor perfor-
mance status.
7
Multiple chemotherapeutic agents have been
studied in the treatment of ASTS.
2–7 Unfortunately,
most of these agents have shown only marginal
response rates. In order to achieve better response
rates and increase survival, higher dose chemo-
therapy regimens have been evaluated. There has
been some evidence of a dose–response relationship
with anthracyclines, first from a report by the MD
Anderson Cancer Centre
8 and then reproduced in
randomized trials by other centres.
9,10 However, this
has not been universally observed: a study of the
EORTC Soft Tissue and Bone Sarcoma Group
failed to show a dose–response relationship with
epirubicin.
11 Similar data have also been seen for
ifosfamide.
12–16 With regards to melphalan, a clear
dose effect was shown in rhabdomyosarcoma xeno-
graft models,
17 and in non-randomized series of
pediatric tumors a response rate of 30% has been
achieved with higher doses.
18 Unfortunately, no
survival benefits have been seen.
The suggestion of a possible dose–response
relationship has driven many centers across the
world to study and implement very high dose
chemotherapy regimens followed by bone marrow
transplantation. Only a few series have been pub-
lished to date.
19–32 Most of these were retrospective
studies accruing very small patient numbers, and no
prospective randomized controlled trials have been
published. Results of these series are conflicting,
some clearly concluding that high dose chemo-
therapy and bone marrow transplant offers no
advantage, others suggesting that survival benefits
may exist, although only by comparison with
historical controls. These positive trials have tended
to include a high proportion of pediatric-type
sarcomas as well as a variable percentage of patients
with no evaluable disease at the time of transplant,
this modality being used as consolidation therapy.
Another confounding issue has been the variety of
conditioning regimens used. Some series describe
the use of a single chemotherapeutic regimen for all
their patients receiving high-dose chemotherapy
while others were not as restrictive and used a variety
of regimens within the same series. The most
popular chemotherapeutic agent is melphalan, most
often combined with etoposide. Total-body irradia-
tion is sometimes used in conjunction with high-dose
chemotherapy.
Given the uncertainties of the previously published
series as well as a desperate need to improve disease-
free survival in patients with advanced sarcomas, the
London Regional Cancer Centre (LRCC) selectively
offered high-dose chemotherapy (HDCT) followed
by autologous stem cell transplant (ASCT) in the
late 1980s and 1990s. We herein present the results
of this retrospective, observational series.
Patients and methods
Eligibility
Patients should be in complete remission (CR) or
have minimal residual disease at time of transplant.
These patients should also be at high risk for relapse
or metastatic disease and must have also shown
chemosensitivity with previous treatments.
Patient characteristics
To identify subjects, the charts of all patients having
received an autologous stem cell transplant at the
LRCC were reviewed, and patients with a diagnosis
of sarcoma were identified. Patient characteristics
at time of diagnosis are summarized in Table 1.
Twenty-four patients with advanced sarcoma
received myeloablative chemotherapy and ASCT
between 1988 and 1998. Twelve were female and
12 were male with a median age of 27 years (range,
12–56 years). At diagnosis, 12 patients (50%) had
Ewing’s sarcoma of bone. The rest had a variety of
histological entities, which included three patients
with primitive neuroectodermal tumors (PNET),
alveolar and embryonal rhabdomyosarcomas (three
patients each), as well as one patient each with
leiomyosarcoma, spindle cell sarcoma and neurosar-
coma. Eleven patients (46%) had metastatic disease
at diagnosis, while 11 others (46%) had locally
advanced disease, e.g., bulky disease without lymph
node involvement. Of the two remaining patients,
Table 1. Patient characteristics at time of diagnosis
Variable (N¼24) Value
(range or percentage)
Parameters at diagnosis:
Median age (years) 24 (range, 11–53)
Histological diagnosis:
Ewing’s sarcoma 12 (50%)
PNET 3 (12.5%)
Alveolar rhabdomyosarcoma 3 (12.5%)
Embryonal rhabdomyosarcoma 3 (12.5%)
Leiomysarcoma 1 (4.2%)
Spindle cell sarcoma 1 (4.2%)
Neurosarcoma 1 (4.2%)
Disease involvement:
Metastases: 12 (50%)
Lungs only 8 (33%)
Bones only 1 (4.2%)
Lungs and bones 1 (4.2%)
Lymph nodes only 1 (4.2%)
Lymph nodes and bones 1 (4.2%)
Locally advanced disease 11 (46%)
Localized disease 2 (8.3%)
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because of disease relapse with subsequent good but
incomplete response to chemotherapy while the
other had a high-risk histological diagnosis (leiomyo-
sarcoma) initially treated with surgery, with
metastatic recurrence in the lungs treated by
metastatectomy after a good partial response to
etoposide. Informed consent was obtained from all
patients.
Prior therapy
All 24 patients were previously treated with chemo-
therapy prior to referral for stem cell transplant.
Most patients had been heavily pretreated prior to
referral with a median number of cycles received of
nine (range, 2–18 cycles). All had either anthra-
cyclines, ifosfamide, or etoposide-based therapy.
Twenty patients received the VAC regimen (vincris-
tine, adriamycin, cyclophosphamide), 18 patients
received ifosfamide and etoposide was used in
17 patients. Eight patients (33%) received two or
more regimens. A total of 42% of the patients
received prior radiation therapy to the site of their
primary disease.
Status at bone marrow transplant
At time of ASCT, the median age was 27 years with
all but one patient being at least 18 years old. Other
patient characteristics at time of ASCT are seen in
Table 2. The median interval between diagnosis and
ASCT was 15 months (range, 9–120 months).
At time of BMT, 15 of the 24 patients (62.5%) of
patients had no evaluable disease. Most were at high
risk of relapse because of a locally advanced or
metastatic presentation and received HDCT and
BMT as consolidative therapy. One patient had
localized disease at first presentation but had the
high-risk histological diagnosis of alveolar rhabdo-
myosarcoma. Seven patients (29%) had residual
disease but had had a good response to chemo-
therapy. Two patients did not meet the planned
eligibility criteria as they had progressive disease but
were accepted for HDCT and ASCT as a last resort.
High-dose chemotherapy regimen
Patients had bone marrow and/or peripheral blood
stem cell (PBSC) collection prior to high-dose
chemotherapy. The first 19 patients only had bone
marrow stem cell collection alone. The last five
patients were transplanted in 1998 and all had
attempts at PBSC collection following 5 days of G-
CSF mobilization. Target PBSC yield was 2.5 10
6
CD34þcells/kg. Three of the five patients had
insufficient CD34-positive cells in their PBSC
collection alone and had combined PBSC/autolo-
gous bone marrow (ABM) reinfusion. One patient
had an adequate PBSC collection and one patient
failed to mobilize CD34-positive cells with G-CSF
and received ABMT only. Patients requiring ABMT
had bone marrow harvesting performed under
general anaesthesia 2–4 weeks before ASCT. The
bone marrow was cryopreserved in DMSO (dimethyl
sulfoxide) and stored in liquid nitrogen at  196 C.
The stem cells were thawed in 40 C water bath at the
bedside. Reinfusion occurred over a maximum of
20min. Bag-injected DNAse was used to disaggre-
gate WBC clumps prior to reinfusion. Prior to
bone marrow harvest, bone marrow biopsies were
performed for all patients and were negative for
malignancy.
All 24 patients received the same myeloablative
regimen. Etoposide 60mg/kg was given on Day  3
as an infusion over 5h. Melphalan 140mg/m
2 was
infused over 30min on Day  2. Reinfusion of stem
cells from bone marrow and/or peripheral collection
occurred on Day 0. Engraftment time (absolute
neutrophil count over 0.5 10
9/l) was a median of
16 days (range 12–25 days). Total body irradiation
was not used for any of the patients.
Statistic analysis
Patients were followed until death or until 15 March
2001. Parametric and nonparametric tests were
used to compare results. Survival curves, constructed
with the date of ASCT as the starting point, were
computed according to the Kaplan–Meier method,
and differences in survival were compared with the
log-rank test for censored data. The Chi-square test
was used to compare median survivals. All P values
are two-sided.
Table 2. Patient characteristics at time of transplant
Variable (N¼24) Value
(range or percentage)
Parameters at ASCT:
Median age (years) 27 (range, 12–56)
Median interval since
diagnosis (months)
15 (range, 9–120)
Disease status:
No evaluable disease 15 (62.5%)
Residual disease with
PR to chemo
7 (29%)
Progressive disease 2 (8%)
Previous therapy:
 1 regimen of chemotherapy 24 (100%)
2 or more regimens 8 (33%)
Median number of cycles 9 (range, 2–18)
Radiation therapy 10 (42%)
Types of chemotherapy
regimen:
VAC 20 (83%)
Ifosfamide 18 (75%)
Etoposide 17 (71%)
PR, partial response; VAC, vincristine, adriamycin,
cyclophosphamide.
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Toxicity
Twenty-four patients received HDCT and ASCT
between 1988 and 1998. All patients experienced the
usual mild to moderate toxicities of mucositis,
nausea, fever and neutropenia. Of these, two patients
(8%) died of direct complications from bone marrow
transplant. One patient suffered a cardiorespiratory
arrest at the time of stem cell infusion. The cause for
this was unknown even after autopsy was performed.
No residual disease was found at postmortem
examination. The patient was 36 years old and had
an original diagnosis of spindle cell sarcoma in
complete remission following seven cycles of doxoru-
bicin. A second patient died of complications of
severe veno-occlusive disease and hepatorenal failure
3 months following transplant. The patient was
20 years old and had an original diagnosis of
PNET. He had been heavily pretreated (16 cycles
of chemotherapy) and had minimal residual disease
at time of ASCT. One patient died of an idiopathic
pulmonary embolus 5 months following ASCT. He
was 54 years old, had Ewing’s sarcoma and had no
evaluable disease at the time of autotransplant or
autopsy.
Survival
Seventeen of 24 patients have now died of their
disease. Of the four patients still alive, three are free
of disease following transplant. One patient relapsed
in the lungs 8 months following transplant and is
still alive with disease 32 months later. Overall, the
median survival is 10 months (range, 0–137þ
months). Of the 18 patients who relapsed, the
median time to relapse was 6 months (range, 2–59
months). Ten of these patients had no evaluable
disease at time of ASCT, while the other eight had
persistent/progressive disease. There was no differ-
ence in time to relapse (TTR) if patients were in CR
at time of ASCT when compared to patients not in
CR, with a median TTR of 6 months (range, 3–59
months) versus 5 months (range, 2–13 months),
respectively. Extent of disease at diagnosis also did
not seem to affect TTR post ASCT. The Kaplan–
Meier survival curve of all patients who received
ASCT is shown in Fig. 1.
For the three patients who are free of recurrent
disease, the median follow-up is 87 months (range,
75–137 months). Prior to transplant, all three
patients had no evaluable disease. Two patients had
Ewing’s sarcoma (at first presentation, one had
metastatic disease to lungs and bones while the
other had locally advanced disease) and the third
patient had locally advanced alveolar rhabdomyosar-
coma. With respect to age, two of the patients were
in their mid-thirties at time of diagnosis and ASCT,
while the third patient was 11 years at diagnosis
and 13 years at transplant. Age therefore did not
appear to affect outcome in this series, either on the
basis of efficacy or toxicity. The fourth patient, who
is alive with recurrence, had an original diagnosis of
Ewing’s sarcoma metastatic to the lungs treated with
chemotherapy and metastatectomy, and also had no
evaluable disease at time of ASCT. Figure 2 shows
the Kaplan–Meier survival curves of patients
according to their disease status at time of ASCT.
The difference between the two curves almost
reaches statistical significance, with a two-sided P
value of 0.07. The 5-year survival estimates are 30%
for patients with no evaluable disease (NED)
compared to 0% in the group with evaluable disease.
The median survivals for both groups, however,
are virtually identical at 10 and 11 months,
respectively.
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Fig. 1. Kaplan–Meier survival curve of overall survival for all patients. Note that the median survival is 10 months and that no
plateau has yet to be discerned.
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diagnosis. The median survival for patients with
Ewing’s sarcoma was 17.5 months compared to 8
months for all other types. However, with small
numbers the P value is non-significant and the curves
are very similar. Furthermore, the 5-year survival rate
estimates were 22 and 17%, respectively.
Discussion
Despite best efforts and aggressive therapy, most
patients treated with high-dose melphalan and
etoposide in this series have now died of their disease
or experienced a recurrence. The overall survival
observed here is no better than that found in reports
from the published literature. Furthermore, the
treatment-related mortality was at least 8%. This is
higher than the 1–2% transplant-related mortality
observed in most series. A possible reason for this
may be the small sample size of our series. However,
one of the two patients had been heavily pretreated
which might explain his excessive morbidity. It is
worth noting that no patients died of infection, the
most common cause of death post transplant. In
our series, specific histological subtypes like Ewing’s
sarcomas did not appear to fare better. However, this
remains unclear in view of our small numbers. Age
also did not appear to be a major predictor of
response to this treatment modality.
There was clearly no benefit from HDCT and
ASCT if patients were not in complete remission.
This is consistent with findings of most of
the previously published series.
19,22,23,27,28,32 The
four patients who are still alive had no evaluable
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Fig. 3. Kaplan–Meier survival curves according to histological type at time of diagnosis. P¼non-significant.
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Fig. 2. Kaplan–Meier survival curves of survival according to disease status. NED, no evaluable disease; P¼0.07.
ASCT for patients with advanced sarcoma 67disease at time of transplant, and in this situation,
HDCT was used as consolidation. It is possible
that these patients may have had a similar good
outcome independent of consolidative therapy.
The patient who relapsed 8 months post-ASCT
underwent resection of his recurrent pulmonary
metastases, and is still alive 32 months later. Thus
surgical intervention could explain his prolonged
survival.
Our data are in contrast with several other
series suggesting improved outcome for HDCT
and ASCT in patients with advanced sar-
coma.
20,21,24,25,27,29,31,32 However, many of these
contained a large number of children
24,25,27–30,32 and
none were randomized. Some series
25,27 restricted
eligibility to patients with Ewing’s sarcoma who had
no evaluable disease at time of transplant. In a recent
series of ASTS, Blay et al.
22 evaluated ifosfamide,
etoposide and cisplatin (VIC) as a myeloablative
regimen. Of the 30 patients treated, eight were in CR
at time of BMT and had a 5-year overall survival
rate of 75%. The remaining 22 patients had a much
lower 5-year survival rate of 5% (P¼0.001). They
concluded that the VIC regimen may be beneficial
in patients with CR at time of transplant and should
be evaluated prospectively.
The overall 5-year survival rate in our series
was 17%. This is similar to the percentage of long-
term survivors among patients with ASTS who
had achieved CR after conventional chemotherapy
in different series: two of 11 (18%) in Dana-Farber
Cancer Institute studies of mesna, doxorubicin,
ifosfamide and dacarbazine (MAID);
33 and 11 of
60 (18%) patients with follow-up of at least
5 years in the large database of studies of
doxorubicin-based chemotherapy in ASTS held
by the European Organization for Research and
Treatment of Cancer Soft Tissue and Bone
Sarcoma Group.
2 In series describing Ewing’s
sarcomas of bone metastatic at diagnosis, results
were similar: 30% survival at 3 years in 122
patients treated in an Intergroup Ewing’s sarcoma
study (IESS);
34 18% survival at 3 years in 48
patients with Ewing’s sarcoma of bone treated in
European Intergroup Cooperative Ewing’s sarcoma
studies (CESS) 81 and 86.
35 In our series, the
5-year survival rate estimate of 30% seen in
patients with no evaluable disease at time of
BMT is only marginally better than those numbers.
Furthermore, in a retrospective analysis of 287
patients randomized to two European Osteosar-
coma Intergroup (EOI) trials, Lewis et al.
36 found
no indication that received dose or dose-intensity
of doxorubicin/cisplatin influenced survival. This
provides more evidence that high-dose chemother-
apy may not be helpful in patients with advanced
sarcoma. Finally, it has now become clear that
HDCT followed by autologous stem cell trans-
plant does not improve survival in women with
metastatic breast cancer,
37 even though this disease
site has well-established chemosensitivity.
In conclusion, in this retrospective series, high-
dose chemotherapy was of no benefit to patients
with advanced sarcoma and should not be used
routinely outside of clinical trials. This has been the
policy in most Canadian centres since the mid-late
1990s. The median overall survival was no better
than that seen in reports from published literature
and treatment-related mortality was at least 8%.
It is possible that patients with Ewing’s sarcoma may
benefit from HDCT plus ASCT, if they have no
evidence of disease when given this treatment, and
future studies should concentrate on this population.
The critical test would be a prospective randomized
trial, which would only be feasible with multicenter
and/or intergroup cooperation and physicians
should consider referring appropriate patients to
the ongoing international Euro-Ewing-Intergroup
EE99 study. Lastly, it is possible that newer and
different combinations of chemotherapeutic agents
like the VIC regimen may prove more effective
than our regimen of melphalan and etoposide.
Autotransplant could be considered as consolidation
earlier in the patients’ treatment course, in order to
circumvent chemoresistance. This may be a reason-
able approach since currently, most of the sarcoma
regimens are quite lengthy with significant toxicity
and impairment of quality of life. Unfortunately, the
negative outcomes observed in randomized con-
trolled trials of patients with metastatic breast cancer,
despite multiple positive small single-arm studies,
may very well predict the results of such trials in
patients with advanced sarcomas, particularly as the
data from many of the single-arm studies are not very
encouraging.
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